Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xu, Richard Pazdur, Geoffrey Kim et al.|The Oncologist|2017Cited by 151
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Lijun Zhang et al.|The Lancet Oncology|2021Cited by 15
FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus.Chana Weinstock, Richard Pazdur, V. Ellen Maher et al.|Journal of Clinical Oncology|2016Cited by 8
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R. Brewer, Julia A. Beaver, Elaine Chang et al.|Clinical Cancer Research|2020Cited by 8